

## Optical Genome Mapping in Hematological Malignancies

Guest Editors:

**Dr. Adam C. Smith**

adam.smith@uhn.ca

**Dr. Alex Hoischen**

alexander.hoischen@  
radboudumc.nl

**Dr. Gordana Raca**

graca@chla.usc.edu

Deadline for manuscript  
submissions:


**31 July 2022**

### Message from the Guest Editors

For more than 40 years, the clinical evaluation of structural variation in hematological malignancies has primarily been driven by karyotyping. Karyotyping is a robust tool for evaluating structural and numerical changes in leukemia and other malignancies due to its ability to visualize and catalogue recurrent changes to chromosomes. As a result, many types of leukemia and lymphoma have a cytogenetic (i.e., karyotyping-based) classification system for diagnosis and prognosis. However, karyotyping suffers from several challenges, including the need for dividing cells (metaphases) and the relatively “low resolution” of the technique. Thus, ancillary testing, such as FISH or RT-PCR, is required to identify specific rearrangements between genes. Optical Genome Mapping is a new technology that can detect structural variation within a sample at a much higher resolution than karyotyping. As such, it is a promising new technique for the clinical evaluation of chromosomal changes in hematologic malignancies.

The aim of this Special Issue is stimulate discussion around the use and adoption of Optical Genome Mapping for clinical diagnostics in hematological malignancies.





## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:**— free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPlus / SciFinder](#), and many other databases.

**Journal Rank:** [JCR - Q1 \(Oncology\)](#) / [CiteScore - Q2 \(Oncology\)](#)

## Contact Us

---

*Cancers*  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
Fax: +41 61 302 89 18  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)